deaths (OS)

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab alone vs. placebo plus SoC 1 1.0better0.35.098 %
pembrolizumab plus SoC vs. placebo plus SoC 2 1.0better0.35.095 %
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 1.0better0.35.082 %